Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Usual Care for NMB Reversal in Hip/Knee Surgery
NCT01422304Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2011
- Primary completion
- Sep 2012
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
A Phase 3 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co.. Started Oct 2011; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT01422304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01422304.